SlideShare a Scribd company logo
Drugs Affecting Blood 
Coagulation 
Chapter 48 
Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
Process of Blood Coagulation 
Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
Blood Vessel Injury 
• Local vasoconstriction seals off small injury 
• Platelet aggregation forms a platelet plug 
• Hageman factor is activated 
• Intrinsic pathway converts prothrombin to thrombin to 
seal system 
• Extrinsic pathway clots the blood that has leaked out of 
the vascular system 
Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
Damaged Vessel Endothelium is a 
Stimulus to Platelets, Causing Platelet 
Adhesion 
Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
Types of Blood Disorders 
• Thromboembolic Disorder 
– Conditions that predispose a person to the formation 
of clots and emboli 
• Hemorrhagic Disorder 
– Disorder in which excess bleeding occurs 
Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
Actions of Anticoagulants 
• Anticoagulants 
– Interfere with the clotting cascade and thrombin 
formation 
Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins 
• Antiplatelets 
– Alter the formation of the platelet plug 
• Thrombolytic Drugs 
– Break down the thrombus that has been formed by 
stimulating the plasmin system
Antiplatelet 
Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins 
• Actions 
– Inhibit platelet adhesion and aggregation by blocking receptors 
sites on the platelet membrane 
– Anagrelide – Blocks the production of platelets in the bone 
marrow 
• Indications 
– Reduce risk of recurrent TIAs or strokes; reduce death or 
nonfatal MI; MI prophylaxis; anti-inflammatory, analgesic, and 
antipyretic effects 
• Pharmacokinetics 
– Well absorbed and bound to plasma proteins 
– Metabolized in the liver and excreted in the urine
Antiplatelet (cont.) 
• Contraindications 
– Allergy, pregnancy, and lactation 
Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins 
• Caution 
– Bleeding disorder, recent surgery, closed-head injury 
• Adverse Effects 
– Bleeding 
– Headache, dizziness, and weakness 
– GI distress 
• Drug-to-Drug Interactions 
– Another drug that affects blood clotting
Question 
How do antiplatelet medications work? 
A. Interfere with the clotting cascade 
B. Alter the formation of the platelet plug 
C. Stimulates the plasmin system 
D. Initiates the clotting cascade 
Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
Answer 
B. Alter the formation of the platelet plug 
Rationale: Antiplatelets alter the formation of the platelet 
plug. 
Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
Anticoagulants and Their Indications 
• Warfarin (Coumadin) 
– Maintains a state of anticoagulation when patient is 
susceptible to potentially dangerous clot formation 
• Heparin (Generic) 
– Inhibits the conversion of prothrombin to thrombin 
• Antithrombin (Thrombate III) 
– Used for hereditary antithrombin III deficiencies; 
replacement therapy in congenital antithrombin III 
deficiency 
Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
Anticoagulants and Their Indications 
(cont.) 
• Argatroban (Acova) 
– Used to treat thrombosis in heparin-induced 
thrombocytopenia 
• Bivalirudin (Angiomax) 
– Used with aspirin to prevent ischemic events in 
patients undergoing transluminal coronary 
angioplasty 
Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
Anticoagulants 
Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins 
• Actions 
– Interfere with the normal cascade of events involved in 
the clotting process 
• Pharmacokinetics 
– Different based on the drug 
• Contraindications 
– Allergy and condition that could be compromised by 
increased bleeding tendencies 
– Pregnancy, renal, or hepatic disorders
Anticoagulants (cont.) 
Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins 
• Caution 
– CHF, thyrotoxicosis, senility, or psychosis 
• Adverse Effects 
– Bleeding 
– GI upset 
– Hepatic dysfunction 
– Alopecia, dermatitis, bone marrow suppression, 
prolonged, and painful erection
Anticoagulants (cont.) 
• Drug-to-Drug Interactions 
– Heparin and oral anticoagulants, salicylates, 
penicillins, or cephalosporins 
– Heparin and nitroglycerine 
– Warfarin – Number of documented interactions 
Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
Low-Molecular-Weight Heparins 
• Inhibit thrombus and clot formation by blocking factors 
Xa and Iia 
• Do not greatly affect thrombin, clotting, or prothrombin 
times; therefore cause fewer systemic adverse effects 
• Block angiogenesis, the process that allows cancer cells 
to develop new blood vessels 
• Are indicated for specific uses in the prevention of clots 
and emboli formation after certain surgeries or bed rest 
Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
Thrombolytic Agents 
Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins 
• Actions 
– Activating plasminogen to plasmin, which in turn 
breaks down fibrin threads in a clot to dissolve a 
formed clot 
• Indications 
– Acute MI, pulmonary emboli, ischemic stroke 
• Pharmacokinetics 
– Drugs must be injected and are cleared from the 
body after liver metabolism 
– Pregnancy and lactation
Thrombolytic Agents (cont.) 
• Contraindications 
– Allergy 
– Any condition that would be worsened by dissolution 
Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins 
of clots 
• Adverse Effects 
– Bleeding 
– Cardiac arrhythmias 
– Hypotension 
– Hypersensitivity – Rash, flushing, bronchospasm, and 
anaphylactic reaction
Thrombolytic Agents (cont.) 
• Drug-to-Drug Interactions 
– Anticoagulants 
– Antiplatelet 
Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
Question 
The pharmacology instructor is talking to the student about 
low-molecular-weight-heparin medications. What would 
the instructor indicate as an advantage to these 
medications? 
A. Indicated for patients who are on an exercise regimen 
B. Initiates angiogenesis 
C. Blocking factors IXa and Iaa 
D. Cause fewer systemic adverse effects 
Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
Answer 
D. Cause fewer systemic adverse effects 
Rationale: Low-molecular-weight-heparins do not greatly 
affect thrombin, clotting, or prothrombin times; therefore 
cause fewer systemic adverse effects. 
Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
Bleeding Disorders Treated With Clotting 
Factors 
Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins 
• Hemophilia 
– Genetic lack of clotting factors that leaves the patient 
vulnerable to excessive bleeding with any injury. 
• Liver Disease 
– Clotting factors and proteins needed for clotting are 
not produced. 
• Bone Marrow Disorders 
– Platelets are not formed in sufficient quantity to be 
effective.
Antihemophilic 
Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins 
• Actions 
– Replace clotting factors that are either genetically 
missing or low in a particular type of hemophilia 
• Indications 
– Prevent blood loss from injury or surgery and to treat 
bleeding disorders 
• Pharmacokinetics 
– Replace normal clotting factors and are processed as 
such by the body
Antihemophilic (cont.) 
• Contraindications 
– Allergy 
– Factor IX in the presence of liver disease 
– Lactation 
Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins 
• Caution 
– Pregnancy
Antihemophilic (cont.) 
• Adverse Effects 
– Involve risks associated with the use of blood 
Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins 
products 
– Headache, flushing, fever, chills, lethargy 
– Nausea and vomiting 
– Stinging, itching, and burning at the site of injection
Systemic Hemostatic Agents 
Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins 
• Actions 
– Stop the natural plasminogen clot-dissolving 
mechanism by blocking its activation or by directly 
inhibiting plasmin. 
• Indications 
– Prevent or treat excess bleeding in hyperfibrinolytic 
states 
• Pharmacokinetics 
– Different for each drug
Systemic Hemostatic Agents (cont.) 
• Contraindications 
– Allergy 
– Acute DIC 
Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins 
• Caution 
– Cardiac disease, renal or hepatic dysfunction, 
pregnancy and lactation
Systemic Hemostatic Agents (cont.) 
• Adverse Effects 
– Excessive clotting 
– CNS – Hallucinations, drowsiness, dizziness, headache, 
and psychotic states 
– GI – Nausea, cramps, diarrhea 
– Weakness, fatigue, malaise, and muscle pain 
– Aprotinin – Cardiac arrhythmias, MI, CHF, and 
hypotension 
• Drug-to-Drug Interactions 
– Heparin 
– Oral contraceptives or estrogen 
Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
Use of Drugs Affecting Coagulation Across 
the Lifespan 
Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
Question 
Please answer the following statement as true or false. 
The indications for use of a systemic hemostatic agent is to 
prevent blood loss from injury or surgery and to treat 
bleeding disorders. 
Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
Answer 
False 
Rationale: Indications for a systemic hemostatic agent 
prevents or treats excess bleeding in hyperfibrinolytic 
states. 
Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
Prototype Antiplatelets 
Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
Prototype Anticoagulants 
Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
Prototype Anticoagulants (Continued) 
Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
Prototype Thrombolytic Agents 
Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
Prototype Antihemophilic 
Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
Prototype Systemic Hemostatic Agents 
Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
Nursing Considerations for Antiplatelet 
Drugs 
• Assessment: History and Physical Exam 
• Nursing Diagnosis 
• Implementation 
• Evaluation 
Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
Nursing Considerations for Anticoagulants 
• Assessment: History and Physical Exam 
• Nursing Diagnosis 
• Implementation 
• Evaluation 
Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
Nursing Considerations for Thrombolytic 
Agents 
• Assessment: History and Physical Exam 
• Nursing Diagnosis 
• Implementation 
• Evaluation 
Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
Nursing Considerations for Antihemophilic 
Agents 
• Assessment: History and Physical Exam 
• Nursing Diagnosis 
• Implementation 
• Evaluation 
Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
Nursing Considerations for Systemic 
Hemostatic Agents 
• Assessment: History and Physical Exam 
• Nursing Diagnosis 
• Implementation 
• Evaluation 
Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
Question 
You are writing a care plan on a patient who is taking an 
anticoagulant. What would be an appropriate nursing 
diagnosis? 
A. Evaluate patient for PT > 2.5 
B. Establish safety precautions 
C. Notify the health care provider of any patient receiving 
this drug 
D. Maintain narcan on standby 
Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
Answer 
B. Establish safety precautions 
Rationale: Patients on anticoagulants are at increased risk 
for bleeding. The following are all important steps to 
protect the patient from blood loss: using soft-bristled 
toothbrushes, using electric instead of straight razors, 
avoiding activities that could easily involve injury, 
limiting invasive procedures, and ensuring adequate 
compression to stop bleeding. 
Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins

More Related Content

What's hot

Ppt chapter 26-1
Ppt chapter 26-1Ppt chapter 26-1
Ppt chapter 26-1stanbridge
 
Ppt chapter 28
Ppt chapter 28Ppt chapter 28
Ppt chapter 28stanbridge
 
Ppt chapter 44
Ppt chapter 44Ppt chapter 44
Ppt chapter 44stanbridge
 
Ppt chapter 31-1
Ppt chapter 31-1Ppt chapter 31-1
Ppt chapter 31-1stanbridge
 
Ppt chapter 48
Ppt chapter 48Ppt chapter 48
Ppt chapter 48stanbridge
 
Ppt chapter 26
Ppt chapter 26Ppt chapter 26
Ppt chapter 26stanbridge
 
Ppt chapter 59
Ppt chapter 59Ppt chapter 59
Ppt chapter 59stanbridge
 
Ppt chapter 41
Ppt chapter 41Ppt chapter 41
Ppt chapter 41stanbridge
 
Ppt chapter 57
Ppt chapter 57Ppt chapter 57
Ppt chapter 57stanbridge
 
Ppt chapter 25
Ppt chapter 25Ppt chapter 25
Ppt chapter 25stanbridge
 
Ppt chapter 31
Ppt chapter 31Ppt chapter 31
Ppt chapter 31stanbridge
 
Cardiovascular System Drugs
Cardiovascular System Drugs Cardiovascular System Drugs
Cardiovascular System Drugs
Dr Shibu Chacko MBE
 
Ppt chapter 43
Ppt chapter 43Ppt chapter 43
Ppt chapter 43stanbridge
 
Ppt chapter 18
Ppt chapter 18Ppt chapter 18
Ppt chapter 18stanbridge
 
Ppt chapter 58
Ppt chapter 58Ppt chapter 58
Ppt chapter 58stanbridge
 
Ppt chapter 33
Ppt chapter 33Ppt chapter 33
Ppt chapter 33stanbridge
 
Ppt chapter 32-1
Ppt chapter 32-1Ppt chapter 32-1
Ppt chapter 32-1stanbridge
 
Ppt chapter 57
Ppt chapter 57Ppt chapter 57
Ppt chapter 57stanbridge
 
Ppt chapter 56
Ppt chapter 56Ppt chapter 56
Ppt chapter 56stanbridge
 
Ppt chapter 37
Ppt chapter 37Ppt chapter 37
Ppt chapter 37stanbridge
 

What's hot (20)

Ppt chapter 26-1
Ppt chapter 26-1Ppt chapter 26-1
Ppt chapter 26-1
 
Ppt chapter 28
Ppt chapter 28Ppt chapter 28
Ppt chapter 28
 
Ppt chapter 44
Ppt chapter 44Ppt chapter 44
Ppt chapter 44
 
Ppt chapter 31-1
Ppt chapter 31-1Ppt chapter 31-1
Ppt chapter 31-1
 
Ppt chapter 48
Ppt chapter 48Ppt chapter 48
Ppt chapter 48
 
Ppt chapter 26
Ppt chapter 26Ppt chapter 26
Ppt chapter 26
 
Ppt chapter 59
Ppt chapter 59Ppt chapter 59
Ppt chapter 59
 
Ppt chapter 41
Ppt chapter 41Ppt chapter 41
Ppt chapter 41
 
Ppt chapter 57
Ppt chapter 57Ppt chapter 57
Ppt chapter 57
 
Ppt chapter 25
Ppt chapter 25Ppt chapter 25
Ppt chapter 25
 
Ppt chapter 31
Ppt chapter 31Ppt chapter 31
Ppt chapter 31
 
Cardiovascular System Drugs
Cardiovascular System Drugs Cardiovascular System Drugs
Cardiovascular System Drugs
 
Ppt chapter 43
Ppt chapter 43Ppt chapter 43
Ppt chapter 43
 
Ppt chapter 18
Ppt chapter 18Ppt chapter 18
Ppt chapter 18
 
Ppt chapter 58
Ppt chapter 58Ppt chapter 58
Ppt chapter 58
 
Ppt chapter 33
Ppt chapter 33Ppt chapter 33
Ppt chapter 33
 
Ppt chapter 32-1
Ppt chapter 32-1Ppt chapter 32-1
Ppt chapter 32-1
 
Ppt chapter 57
Ppt chapter 57Ppt chapter 57
Ppt chapter 57
 
Ppt chapter 56
Ppt chapter 56Ppt chapter 56
Ppt chapter 56
 
Ppt chapter 37
Ppt chapter 37Ppt chapter 37
Ppt chapter 37
 

Viewers also liked

High dose statins in plaque stabilization
High dose statins in plaque stabilization High dose statins in plaque stabilization
High dose statins in plaque stabilization
ALEXANDRU ANDRITOIU
 
basics of tissue
basics of tissuebasics of tissue
basics of tissue
Poonam Bhullar
 
pembekuan darah
pembekuan darahpembekuan darah
pembekuan darah
Anindita Geovani
 
Seminar on Anticoagulant
Seminar on AnticoagulantSeminar on Anticoagulant
Seminar on Anticoagulant
KULDIP DEKA
 
Blood composition and its functions on 17.09.2016
Blood composition and its functions  on 17.09.2016Blood composition and its functions  on 17.09.2016
Blood composition and its functions on 17.09.2016
Biji Saro
 
Statins 5-15
Statins 5-15Statins 5-15
Statins 5-15
qualityinhealth
 
blood cogulants and anticogulants.....
blood cogulants and anticogulants.....blood cogulants and anticogulants.....
blood cogulants and anticogulants.....Rohit Bisht
 
Presentation by neha jain on aspirin induced alterations on liver and kidney
Presentation by neha jain on aspirin induced alterations on liver and kidneyPresentation by neha jain on aspirin induced alterations on liver and kidney
Presentation by neha jain on aspirin induced alterations on liver and kidney
neha jain
 
Nursing care of client with Coronary artery disease part 2 of 2
Nursing care of client with Coronary artery disease part 2 of 2Nursing care of client with Coronary artery disease part 2 of 2
Nursing care of client with Coronary artery disease part 2 of 2
Carmela Domocmat
 
การพยาบาลDhf
การพยาบาลDhfการพยาบาลDhf
การพยาบาลDhfMaytinee Beudam
 
BLOOD GROUP SYSTEM
BLOOD GROUP SYSTEMBLOOD GROUP SYSTEM
BLOOD GROUP SYSTEM
Dr Nilesh Kate
 
Ppt coagulation and flocculation
Ppt coagulation and flocculationPpt coagulation and flocculation
Ppt coagulation and flocculation
Lokesh Saini
 
Pharmacology of Drugs Affecting Blood
Pharmacology of Drugs Affecting BloodPharmacology of Drugs Affecting Blood
Pharmacology of Drugs Affecting Blood
Ganapathy Tamilselvan
 
Rh Blood Group System
Rh Blood Group SystemRh Blood Group System
Rh Blood Group SystemZahoor Ahmed
 
Blood group.007[1]
Blood group.007[1]Blood group.007[1]
Blood group.007[1]
Pallav Desai
 
Hamostasis and blood coagulation
Hamostasis and blood coagulationHamostasis and blood coagulation
Hamostasis and blood coagulationdrmcbansal
 
Blood coagulation
Blood coagulationBlood coagulation
Blood coagulation
mehakchhokra11
 
Anticoagulant, antithrombotic and anti platelet drugs
Anticoagulant, antithrombotic and anti platelet drugsAnticoagulant, antithrombotic and anti platelet drugs
Anticoagulant, antithrombotic and anti platelet drugsraj kumar
 

Viewers also liked (19)

High dose statins in plaque stabilization
High dose statins in plaque stabilization High dose statins in plaque stabilization
High dose statins in plaque stabilization
 
basics of tissue
basics of tissuebasics of tissue
basics of tissue
 
pembekuan darah
pembekuan darahpembekuan darah
pembekuan darah
 
Seminar on Anticoagulant
Seminar on AnticoagulantSeminar on Anticoagulant
Seminar on Anticoagulant
 
Blood composition and its functions on 17.09.2016
Blood composition and its functions  on 17.09.2016Blood composition and its functions  on 17.09.2016
Blood composition and its functions on 17.09.2016
 
Statins 5-15
Statins 5-15Statins 5-15
Statins 5-15
 
blood cogulants and anticogulants.....
blood cogulants and anticogulants.....blood cogulants and anticogulants.....
blood cogulants and anticogulants.....
 
Presentation by neha jain on aspirin induced alterations on liver and kidney
Presentation by neha jain on aspirin induced alterations on liver and kidneyPresentation by neha jain on aspirin induced alterations on liver and kidney
Presentation by neha jain on aspirin induced alterations on liver and kidney
 
Nursing care of client with Coronary artery disease part 2 of 2
Nursing care of client with Coronary artery disease part 2 of 2Nursing care of client with Coronary artery disease part 2 of 2
Nursing care of client with Coronary artery disease part 2 of 2
 
การพยาบาลDhf
การพยาบาลDhfการพยาบาลDhf
การพยาบาลDhf
 
BLOOD GROUP SYSTEM
BLOOD GROUP SYSTEMBLOOD GROUP SYSTEM
BLOOD GROUP SYSTEM
 
Ppt coagulation and flocculation
Ppt coagulation and flocculationPpt coagulation and flocculation
Ppt coagulation and flocculation
 
Pharmacology of Drugs Affecting Blood
Pharmacology of Drugs Affecting BloodPharmacology of Drugs Affecting Blood
Pharmacology of Drugs Affecting Blood
 
Rh Blood Group System
Rh Blood Group SystemRh Blood Group System
Rh Blood Group System
 
Blood group.007[1]
Blood group.007[1]Blood group.007[1]
Blood group.007[1]
 
Hamostasis and blood coagulation
Hamostasis and blood coagulationHamostasis and blood coagulation
Hamostasis and blood coagulation
 
Blood group
Blood groupBlood group
Blood group
 
Blood coagulation
Blood coagulationBlood coagulation
Blood coagulation
 
Anticoagulant, antithrombotic and anti platelet drugs
Anticoagulant, antithrombotic and anti platelet drugsAnticoagulant, antithrombotic and anti platelet drugs
Anticoagulant, antithrombotic and anti platelet drugs
 

Similar to Ppt chapter 48

Ppt chapter 52
Ppt chapter 52Ppt chapter 52
Ppt chapter 52stanbridge
 
Ppt chapter 32
Ppt chapter 32Ppt chapter 32
Ppt chapter 32stanbridge
 
Ppt chapter 36-1
Ppt chapter 36-1Ppt chapter 36-1
Ppt chapter 36-1stanbridge
 
Ppt chapter 16-1
Ppt chapter 16-1Ppt chapter 16-1
Ppt chapter 16-1stanbridge
 
Ppt chapter 59
Ppt chapter 59Ppt chapter 59
Ppt chapter 59stanbridge
 
Ppt chapter 16
Ppt chapter 16Ppt chapter 16
Ppt chapter 16stanbridge
 
Ppt chapter 40
Ppt chapter 40Ppt chapter 40
Ppt chapter 40stanbridge
 
Ppt chapter 36
Ppt chapter 36Ppt chapter 36
Ppt chapter 36stanbridge
 
Ppt chapter 24
Ppt chapter 24Ppt chapter 24
Ppt chapter 24stanbridge
 
Ppt chapter 24-1
Ppt chapter 24-1Ppt chapter 24-1
Ppt chapter 24-1stanbridge
 
Ppt chapter 35-1
Ppt chapter 35-1Ppt chapter 35-1
Ppt chapter 35-1stanbridge
 
Ppt chapter 35-1
Ppt chapter 35-1Ppt chapter 35-1
Ppt chapter 35-1stanbridge
 
Ppt chapter 35-1
Ppt chapter 35-1Ppt chapter 35-1
Ppt chapter 35-1stanbridge
 
Ppt chapter 38-1
Ppt chapter 38-1Ppt chapter 38-1
Ppt chapter 38-1stanbridge
 
Ppt chapter 37-1
Ppt chapter 37-1Ppt chapter 37-1
Ppt chapter 37-1stanbridge
 
management and assessment of patient with hemaetologic desorder
management and assessment of patient with hemaetologic desordermanagement and assessment of patient with hemaetologic desorder
management and assessment of patient with hemaetologic desorder
Kalinga Institute of Medical Sciences
 
Ppt chapter 51
Ppt chapter 51Ppt chapter 51
Ppt chapter 51stanbridge
 
Ppt chapter 42
Ppt chapter 42Ppt chapter 42
Ppt chapter 42stanbridge
 
Ppt chapter 20
Ppt chapter 20Ppt chapter 20
Ppt chapter 20stanbridge
 
Ppt chapter 20
Ppt chapter 20Ppt chapter 20
Ppt chapter 20stanbridge
 

Similar to Ppt chapter 48 (20)

Ppt chapter 52
Ppt chapter 52Ppt chapter 52
Ppt chapter 52
 
Ppt chapter 32
Ppt chapter 32Ppt chapter 32
Ppt chapter 32
 
Ppt chapter 36-1
Ppt chapter 36-1Ppt chapter 36-1
Ppt chapter 36-1
 
Ppt chapter 16-1
Ppt chapter 16-1Ppt chapter 16-1
Ppt chapter 16-1
 
Ppt chapter 59
Ppt chapter 59Ppt chapter 59
Ppt chapter 59
 
Ppt chapter 16
Ppt chapter 16Ppt chapter 16
Ppt chapter 16
 
Ppt chapter 40
Ppt chapter 40Ppt chapter 40
Ppt chapter 40
 
Ppt chapter 36
Ppt chapter 36Ppt chapter 36
Ppt chapter 36
 
Ppt chapter 24
Ppt chapter 24Ppt chapter 24
Ppt chapter 24
 
Ppt chapter 24-1
Ppt chapter 24-1Ppt chapter 24-1
Ppt chapter 24-1
 
Ppt chapter 35-1
Ppt chapter 35-1Ppt chapter 35-1
Ppt chapter 35-1
 
Ppt chapter 35-1
Ppt chapter 35-1Ppt chapter 35-1
Ppt chapter 35-1
 
Ppt chapter 35-1
Ppt chapter 35-1Ppt chapter 35-1
Ppt chapter 35-1
 
Ppt chapter 38-1
Ppt chapter 38-1Ppt chapter 38-1
Ppt chapter 38-1
 
Ppt chapter 37-1
Ppt chapter 37-1Ppt chapter 37-1
Ppt chapter 37-1
 
management and assessment of patient with hemaetologic desorder
management and assessment of patient with hemaetologic desordermanagement and assessment of patient with hemaetologic desorder
management and assessment of patient with hemaetologic desorder
 
Ppt chapter 51
Ppt chapter 51Ppt chapter 51
Ppt chapter 51
 
Ppt chapter 42
Ppt chapter 42Ppt chapter 42
Ppt chapter 42
 
Ppt chapter 20
Ppt chapter 20Ppt chapter 20
Ppt chapter 20
 
Ppt chapter 20
Ppt chapter 20Ppt chapter 20
Ppt chapter 20
 

More from stanbridge

Micro Lab 3 Lecture
Micro Lab 3 LectureMicro Lab 3 Lecture
Micro Lab 3 Lecture
stanbridge
 
Creating a poster v2
Creating a poster v2Creating a poster v2
Creating a poster v2
stanbridge
 
Creating a poster
Creating a posterCreating a poster
Creating a poster
stanbridge
 
Sample poster
Sample posterSample poster
Sample poster
stanbridge
 
OT 5018 Thesis Dissemination
OT 5018 Thesis DisseminationOT 5018 Thesis Dissemination
OT 5018 Thesis Dissemination
stanbridge
 
Ot5101 005 week 5
Ot5101 005 week 5Ot5101 005 week 5
Ot5101 005 week 5
stanbridge
 
Ot5101 005 week4
Ot5101 005 week4Ot5101 005 week4
Ot5101 005 week4
stanbridge
 
Compliance, motivation, and health behaviors
Compliance, motivation, and health behaviors Compliance, motivation, and health behaviors
Compliance, motivation, and health behaviors
stanbridge
 
Ch 5 developmental stages of the learner
Ch 5   developmental stages of the learnerCh 5   developmental stages of the learner
Ch 5 developmental stages of the learner
stanbridge
 
OT 5101 week2 theory policy
OT 5101 week2 theory policyOT 5101 week2 theory policy
OT 5101 week2 theory policy
stanbridge
 
OT 5101 week3 planning needs assessment
OT 5101 week3 planning needs assessmentOT 5101 week3 planning needs assessment
OT 5101 week3 planning needs assessment
stanbridge
 
Ot5101 week1
Ot5101 week1Ot5101 week1
Ot5101 week1
stanbridge
 
NUR 304 Chapter005
NUR 304 Chapter005NUR 304 Chapter005
NUR 304 Chapter005
stanbridge
 
NUR 3043 Chapter007
NUR 3043 Chapter007NUR 3043 Chapter007
NUR 3043 Chapter007
stanbridge
 
NUR 3043 Chapter006
NUR 3043 Chapter006NUR 3043 Chapter006
NUR 3043 Chapter006
stanbridge
 
NUR 3043 Chapter004
NUR 3043 Chapter004NUR 3043 Chapter004
NUR 3043 Chapter004
stanbridge
 
3043 Chapter009
3043 Chapter0093043 Chapter009
3043 Chapter009
stanbridge
 
3043 Chapter008
 3043 Chapter008 3043 Chapter008
3043 Chapter008
stanbridge
 
Melnyk ppt chapter_21
Melnyk ppt chapter_21Melnyk ppt chapter_21
Melnyk ppt chapter_21
stanbridge
 
Melnyk ppt chapter_22
Melnyk ppt chapter_22Melnyk ppt chapter_22
Melnyk ppt chapter_22
stanbridge
 

More from stanbridge (20)

Micro Lab 3 Lecture
Micro Lab 3 LectureMicro Lab 3 Lecture
Micro Lab 3 Lecture
 
Creating a poster v2
Creating a poster v2Creating a poster v2
Creating a poster v2
 
Creating a poster
Creating a posterCreating a poster
Creating a poster
 
Sample poster
Sample posterSample poster
Sample poster
 
OT 5018 Thesis Dissemination
OT 5018 Thesis DisseminationOT 5018 Thesis Dissemination
OT 5018 Thesis Dissemination
 
Ot5101 005 week 5
Ot5101 005 week 5Ot5101 005 week 5
Ot5101 005 week 5
 
Ot5101 005 week4
Ot5101 005 week4Ot5101 005 week4
Ot5101 005 week4
 
Compliance, motivation, and health behaviors
Compliance, motivation, and health behaviors Compliance, motivation, and health behaviors
Compliance, motivation, and health behaviors
 
Ch 5 developmental stages of the learner
Ch 5   developmental stages of the learnerCh 5   developmental stages of the learner
Ch 5 developmental stages of the learner
 
OT 5101 week2 theory policy
OT 5101 week2 theory policyOT 5101 week2 theory policy
OT 5101 week2 theory policy
 
OT 5101 week3 planning needs assessment
OT 5101 week3 planning needs assessmentOT 5101 week3 planning needs assessment
OT 5101 week3 planning needs assessment
 
Ot5101 week1
Ot5101 week1Ot5101 week1
Ot5101 week1
 
NUR 304 Chapter005
NUR 304 Chapter005NUR 304 Chapter005
NUR 304 Chapter005
 
NUR 3043 Chapter007
NUR 3043 Chapter007NUR 3043 Chapter007
NUR 3043 Chapter007
 
NUR 3043 Chapter006
NUR 3043 Chapter006NUR 3043 Chapter006
NUR 3043 Chapter006
 
NUR 3043 Chapter004
NUR 3043 Chapter004NUR 3043 Chapter004
NUR 3043 Chapter004
 
3043 Chapter009
3043 Chapter0093043 Chapter009
3043 Chapter009
 
3043 Chapter008
 3043 Chapter008 3043 Chapter008
3043 Chapter008
 
Melnyk ppt chapter_21
Melnyk ppt chapter_21Melnyk ppt chapter_21
Melnyk ppt chapter_21
 
Melnyk ppt chapter_22
Melnyk ppt chapter_22Melnyk ppt chapter_22
Melnyk ppt chapter_22
 

Ppt chapter 48

  • 1. Drugs Affecting Blood Coagulation Chapter 48 Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
  • 2. Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
  • 3. Process of Blood Coagulation Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
  • 4. Blood Vessel Injury • Local vasoconstriction seals off small injury • Platelet aggregation forms a platelet plug • Hageman factor is activated • Intrinsic pathway converts prothrombin to thrombin to seal system • Extrinsic pathway clots the blood that has leaked out of the vascular system Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
  • 5. Damaged Vessel Endothelium is a Stimulus to Platelets, Causing Platelet Adhesion Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
  • 6. Types of Blood Disorders • Thromboembolic Disorder – Conditions that predispose a person to the formation of clots and emboli • Hemorrhagic Disorder – Disorder in which excess bleeding occurs Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
  • 7. Actions of Anticoagulants • Anticoagulants – Interfere with the clotting cascade and thrombin formation Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins • Antiplatelets – Alter the formation of the platelet plug • Thrombolytic Drugs – Break down the thrombus that has been formed by stimulating the plasmin system
  • 8. Antiplatelet Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins • Actions – Inhibit platelet adhesion and aggregation by blocking receptors sites on the platelet membrane – Anagrelide – Blocks the production of platelets in the bone marrow • Indications – Reduce risk of recurrent TIAs or strokes; reduce death or nonfatal MI; MI prophylaxis; anti-inflammatory, analgesic, and antipyretic effects • Pharmacokinetics – Well absorbed and bound to plasma proteins – Metabolized in the liver and excreted in the urine
  • 9. Antiplatelet (cont.) • Contraindications – Allergy, pregnancy, and lactation Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins • Caution – Bleeding disorder, recent surgery, closed-head injury • Adverse Effects – Bleeding – Headache, dizziness, and weakness – GI distress • Drug-to-Drug Interactions – Another drug that affects blood clotting
  • 10. Question How do antiplatelet medications work? A. Interfere with the clotting cascade B. Alter the formation of the platelet plug C. Stimulates the plasmin system D. Initiates the clotting cascade Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
  • 11. Answer B. Alter the formation of the platelet plug Rationale: Antiplatelets alter the formation of the platelet plug. Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
  • 12. Anticoagulants and Their Indications • Warfarin (Coumadin) – Maintains a state of anticoagulation when patient is susceptible to potentially dangerous clot formation • Heparin (Generic) – Inhibits the conversion of prothrombin to thrombin • Antithrombin (Thrombate III) – Used for hereditary antithrombin III deficiencies; replacement therapy in congenital antithrombin III deficiency Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
  • 13. Anticoagulants and Their Indications (cont.) • Argatroban (Acova) – Used to treat thrombosis in heparin-induced thrombocytopenia • Bivalirudin (Angiomax) – Used with aspirin to prevent ischemic events in patients undergoing transluminal coronary angioplasty Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
  • 14. Anticoagulants Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins • Actions – Interfere with the normal cascade of events involved in the clotting process • Pharmacokinetics – Different based on the drug • Contraindications – Allergy and condition that could be compromised by increased bleeding tendencies – Pregnancy, renal, or hepatic disorders
  • 15. Anticoagulants (cont.) Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins • Caution – CHF, thyrotoxicosis, senility, or psychosis • Adverse Effects – Bleeding – GI upset – Hepatic dysfunction – Alopecia, dermatitis, bone marrow suppression, prolonged, and painful erection
  • 16. Anticoagulants (cont.) • Drug-to-Drug Interactions – Heparin and oral anticoagulants, salicylates, penicillins, or cephalosporins – Heparin and nitroglycerine – Warfarin – Number of documented interactions Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
  • 17. Low-Molecular-Weight Heparins • Inhibit thrombus and clot formation by blocking factors Xa and Iia • Do not greatly affect thrombin, clotting, or prothrombin times; therefore cause fewer systemic adverse effects • Block angiogenesis, the process that allows cancer cells to develop new blood vessels • Are indicated for specific uses in the prevention of clots and emboli formation after certain surgeries or bed rest Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
  • 18. Thrombolytic Agents Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins • Actions – Activating plasminogen to plasmin, which in turn breaks down fibrin threads in a clot to dissolve a formed clot • Indications – Acute MI, pulmonary emboli, ischemic stroke • Pharmacokinetics – Drugs must be injected and are cleared from the body after liver metabolism – Pregnancy and lactation
  • 19. Thrombolytic Agents (cont.) • Contraindications – Allergy – Any condition that would be worsened by dissolution Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins of clots • Adverse Effects – Bleeding – Cardiac arrhythmias – Hypotension – Hypersensitivity – Rash, flushing, bronchospasm, and anaphylactic reaction
  • 20. Thrombolytic Agents (cont.) • Drug-to-Drug Interactions – Anticoagulants – Antiplatelet Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
  • 21. Question The pharmacology instructor is talking to the student about low-molecular-weight-heparin medications. What would the instructor indicate as an advantage to these medications? A. Indicated for patients who are on an exercise regimen B. Initiates angiogenesis C. Blocking factors IXa and Iaa D. Cause fewer systemic adverse effects Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
  • 22. Answer D. Cause fewer systemic adverse effects Rationale: Low-molecular-weight-heparins do not greatly affect thrombin, clotting, or prothrombin times; therefore cause fewer systemic adverse effects. Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
  • 23. Bleeding Disorders Treated With Clotting Factors Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins • Hemophilia – Genetic lack of clotting factors that leaves the patient vulnerable to excessive bleeding with any injury. • Liver Disease – Clotting factors and proteins needed for clotting are not produced. • Bone Marrow Disorders – Platelets are not formed in sufficient quantity to be effective.
  • 24. Antihemophilic Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins • Actions – Replace clotting factors that are either genetically missing or low in a particular type of hemophilia • Indications – Prevent blood loss from injury or surgery and to treat bleeding disorders • Pharmacokinetics – Replace normal clotting factors and are processed as such by the body
  • 25. Antihemophilic (cont.) • Contraindications – Allergy – Factor IX in the presence of liver disease – Lactation Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins • Caution – Pregnancy
  • 26. Antihemophilic (cont.) • Adverse Effects – Involve risks associated with the use of blood Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins products – Headache, flushing, fever, chills, lethargy – Nausea and vomiting – Stinging, itching, and burning at the site of injection
  • 27. Systemic Hemostatic Agents Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins • Actions – Stop the natural plasminogen clot-dissolving mechanism by blocking its activation or by directly inhibiting plasmin. • Indications – Prevent or treat excess bleeding in hyperfibrinolytic states • Pharmacokinetics – Different for each drug
  • 28. Systemic Hemostatic Agents (cont.) • Contraindications – Allergy – Acute DIC Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins • Caution – Cardiac disease, renal or hepatic dysfunction, pregnancy and lactation
  • 29. Systemic Hemostatic Agents (cont.) • Adverse Effects – Excessive clotting – CNS – Hallucinations, drowsiness, dizziness, headache, and psychotic states – GI – Nausea, cramps, diarrhea – Weakness, fatigue, malaise, and muscle pain – Aprotinin – Cardiac arrhythmias, MI, CHF, and hypotension • Drug-to-Drug Interactions – Heparin – Oral contraceptives or estrogen Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
  • 30. Use of Drugs Affecting Coagulation Across the Lifespan Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
  • 31. Question Please answer the following statement as true or false. The indications for use of a systemic hemostatic agent is to prevent blood loss from injury or surgery and to treat bleeding disorders. Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
  • 32. Answer False Rationale: Indications for a systemic hemostatic agent prevents or treats excess bleeding in hyperfibrinolytic states. Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
  • 33. Prototype Antiplatelets Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
  • 34. Prototype Anticoagulants Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
  • 35. Prototype Anticoagulants (Continued) Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
  • 36. Prototype Thrombolytic Agents Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
  • 37. Prototype Antihemophilic Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
  • 38. Prototype Systemic Hemostatic Agents Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
  • 39. Nursing Considerations for Antiplatelet Drugs • Assessment: History and Physical Exam • Nursing Diagnosis • Implementation • Evaluation Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
  • 40. Nursing Considerations for Anticoagulants • Assessment: History and Physical Exam • Nursing Diagnosis • Implementation • Evaluation Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
  • 41. Nursing Considerations for Thrombolytic Agents • Assessment: History and Physical Exam • Nursing Diagnosis • Implementation • Evaluation Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
  • 42. Nursing Considerations for Antihemophilic Agents • Assessment: History and Physical Exam • Nursing Diagnosis • Implementation • Evaluation Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
  • 43. Nursing Considerations for Systemic Hemostatic Agents • Assessment: History and Physical Exam • Nursing Diagnosis • Implementation • Evaluation Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
  • 44. Question You are writing a care plan on a patient who is taking an anticoagulant. What would be an appropriate nursing diagnosis? A. Evaluate patient for PT > 2.5 B. Establish safety precautions C. Notify the health care provider of any patient receiving this drug D. Maintain narcan on standby Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
  • 45. Answer B. Establish safety precautions Rationale: Patients on anticoagulants are at increased risk for bleeding. The following are all important steps to protect the patient from blood loss: using soft-bristled toothbrushes, using electric instead of straight razors, avoiding activities that could easily involve injury, limiting invasive procedures, and ensuring adequate compression to stop bleeding. Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins